X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TEVA PHARMA (Israel) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
TEVA PHARMA
Dec-13
AUROBINDO PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8952,704-   
Low Rs6222,349-   
Sales per share (Unadj.) Rs254.61,551.8-  
Earnings per share (Unadj.) Rs39.396.9-  
Cash flow per share (Unadj.) Rs46.6222.4-  
Dividends per share (Unadj.) Rs2.5084.86-  
Dividend yield (eoy) %0.33.4 9.8%  
Book value per share (Unadj.) Rs160.01,723.8-  
Shares outstanding (eoy) m585.88848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 183.0%   
Avg P/E ratio x19.326.1 74.1%  
P/CF ratio (eoy) x16.311.4 143.3%  
Price / Book Value ratio x4.71.5 323.5%  
Dividend payout %6.487.5 7.3%   
Avg Mkt Cap Rs m444,3902,142,404 20.7%   
No. of employees `00014.044.9 31.1%   
Total wages/salary Rs m17,6780-   
Avg. sales/employee Rs Th10,667.829,278.9 36.4%   
Avg. wages/employee Rs Th1,264.30-   
Avg. net profit/employee Rs Th1,645.81,829.0 90.0%   
INCOME DATA
Net Sales Rs m149,1571,315,941 11.3%  
Other income Rs m1,1590-   
Total revenues Rs m150,3161,315,941 11.4%   
Gross profit Rs m34,343360,371 9.5%  
Depreciation Rs m4,276106,369 4.0%   
Interest Rs m66725,847 2.6%   
Profit before tax Rs m30,558228,155 13.4%   
Minority Interest Rs m501,036 4.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-149,771 0.0%   
Tax Rs m7,597-2,786 -272.7%   
Profit after tax Rs m23,01282,206 28.0%  
Gross profit margin %23.027.4 84.1%  
Effective tax rate %24.9-1.2 -2,036.1%   
Net profit margin %15.46.2 247.0%  
BALANCE SHEET DATA
Current assets Rs m92,062888,782 10.4%   
Current liabilities Rs m66,223775,093 8.5%   
Net working cap to sales %17.38.6 200.5%  
Current ratio x1.41.1 121.2%  
Inventory Days Days10691 116.7%  
Debtors Days Days6896 70.6%  
Net fixed assets Rs m62,919429,815 14.6%   
Share capital Rs m5863,239 18.1%   
"Free" reserves Rs m93,1330-   
Net worth Rs m93,7191,461,761 6.4%   
Long term debt Rs m1,814672,870 0.3%   
Total assets Rs m162,4943,007,347 5.4%  
Interest coverage x46.89.8 476.2%   
Debt to equity ratio x00.5 4.2%  
Sales to assets ratio x0.90.4 209.8%   
Return on assets %14.63.6 405.6%  
Return on equity %24.65.6 436.6%  
Return on capital %32.74.9 663.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m45,6130-   
CASH FLOW
From Operations Rs m32,786209,693 15.6%  
From Investments Rs m-17,870-74,303 24.1%  
From Financial Activity Rs m-19,153-251,541 7.6%  
Net Cashflow Rs m-4,239-116,151 3.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare AUROBINDO PHARMA With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC PHARMA  UNICHEM LAB  ALEMBIC LTD  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - SANOFI INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS